Controlling resorption of bioresorbable medical implant material

ABSTRACT

The resorption of a medical implant can be controlled with the use of particles embedded in a resorbable bulk material forming the implant or portion thereof. The implant can be removed from a body of a mammal by natural biological mechanisms after use. The resorption of the implant can involve swelling and/or hydrolyzing of the particles within the implant upon contact with a body fluid such that porosity and flow of fluid within the bulk material of the implant is increased. Resorption of the implant may also involve the use of particles with magnetic properties embedded within the implant such that an applied magnetic field causes the particles to vibrate within the bulk material thereby increasing the porosity and thus the flow of fluid, hence facilitating resorption of the implant. The resorption rate of the implant can be controlled by modulating swelling, hydrolysis, or movement of the embedded particles.

RELATED APPLICATION SECTION

This application is a continuation of co-pending U.S. patent applicationSer. No. 12/960,185, filed Dec. 3, 2010 which is a divisional of Ser.No. 12/072,371 filed Feb. 26, 2008, now U.S. Pat. No. 7,910,125 issuedon Mar. 22, 2011, which is a division of U.S. patent application Ser.No. 11/158,154, filed Jun. 21, 2005, now U.S. Pat. No. 7,335,375 issuedFeb. 26, 2008, which is a divisional of U.S. patent application Ser. No.09/813,780, filed Mar. 21, 2001, now U.S. Pat. No. 6,913,765 issued Jul.5, 2005, all of which are incorporated by reference in their entiretiesherein.

TECHNICAL FIELD

This invention generally relates to medical implants. More particularly,the invention relates to devices, methods, and compositions for use inmedical implants that resorb in a body of a mammal.

BACKGROUND INFORMATION

Medical implants have a variety of applications including kidneydrainage and vascular surgery. Examples of medical implants include aureteral stent used for drainage of urine from the kidney to the bladderand a vascular graft used for maintaining blood flow. Medical implantsgenerally have to be removed from the body by an invasive procedure.Medical implants that are left in vivo after use may cause complicationssuch as inflammation and other foreign body responses.

SUMMARY OF THE INVENTION

In accordance with the invention, a medical implant is removed from apatient's body by non-invasive means, such as by resorption of themedical implant by natural biological mechanisms. Non-invasive removalof a medical implant avoids pain and suffering often associated withinvasive and surgical procedures. In addition, a non-invasive removalprocedure reduces medical expenses and lost productivity of the patient.

The present invention relates to compositions, devices, and methods thatare useful in controlled in vivo resorption of bioresorbable medicalimplants, as by resorption of the implant material followed by normalelimination in a body fluid such as urine or feces. By using naturalbiological mechanisms of elimination, patient discomfort and the risk ofcomplications to the patient is minimized compared to invasiveprocedures, such as surgical or endoscope procedures. Another objectiveof this invention is to provide procedures in which removal of animplant is non-invasive, controllable, and predictable. In oneembodiment, the rate of removal of the implant is pre-selectable.Medical implants according to the invention can take various shapes andcan include stents, catheters, cannulas, plugs, fillers, constrictors,sheets, bone anchors, plates, rods, seeds, and tubes, for example.

In one aspect, the invention generally features a composition for use ina medical device in a mammal (such as a human or an animal) thatincludes a bioresorbable bulk material and particles embedded therein.The particles cause the bioresorbable bulk material to resorb at acontrollable rate upon contact with a body fluid. The compositions,medical devices, and methods of the invention generally are suitable foruse in any mammal including a human or animal. In one embodiment, themedical device includes a bioresorbable bulk material with embeddedresorbable particles causing the bioresorbable bulk material to resorbat a controllable resorption rate upon contact with a body fluid. Theembedded particles have a different and faster resorption rate than thebioresorbable bulk material and cause the bioresorbable bulk material toresorb upon contact with a body fluid. In another embodiment, themedical device includes a bioresorbable bulk material with embeddedparticles having magnetic properties.

The composition of the invention may include a bulk bioresorbablematerial of ionically crosslinked polymeric materials, e.g., anionically crosslinked polymer hydrogel and having a water content ofless than 90% by weight and possesses sufficient mechanical strength toserve as any of the medical implants mentioned above. Each of theresorbable particles may include, for example, an organic compound, asoluble or degradable inorganic compound, a sugar or water-solubleorganic salt, an organic or inorganic crystal powder aggregate, or awater-swellable polymer.

In another aspect, the invention generally features a method forcontrolling resorption of a bioresorbable material in a medical devicefor use in a mammal. In one embodiment, the method includes the steps ofproviding a bioresorbable bulk material, embedding resorbable particlesin the bioresorbable bulk material, and contacting a body fluid with themedical device thereby causing the bioresorbable bulk material to resorbat a controllable resorption rate. The particles can have a differentand faster resorption rate than that of the bioresorbable bulk material.

In another embodiment, a method for controlling resorption of abioresorbable material in a medical device includes providing abioresorbable bulk material, embedding in the bioresorbable bulkmaterial particles having a pre-selected magnetic property, exposing themedical device to a magnetic field, and inducing activation and/orvibration of the particles thereby causing the bioresorbable bulkmaterial to resorb at a controllable resorption rate.

In yet another embodiment, a method for controlling resorption of abioresorbable material in a medical device includes providing abioresorbable bulk material shaped as a medical device, providing acoating material including a dissolvable polymeric material that allowsfor diffusion of a body fluid through the coating material at apre-selected rate, and coating the medical device with the coatingmaterial.

In yet another aspect, the invention generally features a system forcontrolled delivery in the body of a mammal of a pharmaceutical agent.The system includes a carrier device having coated thereon abioresorbable, ionically or covalently crosslinked polymeric materialand incorporated therein a pharmaceutical agent.

In yet another aspect, the invention generally features a coatingmaterial for use in a medical device for regulating resorption of themedical device. The coating material includes a bioresorbable ionicallyor covalently crosslinked polymeric material that allows diffusion intothe medical device by a body fluid at a controllable rate.

These and other features, aspects, and advantages will become moreapparent from the following description, drawings, and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings are not necessarily to scale, emphasis instead generallybeing placed upon illustrating the principles of the invention.

FIGS. 1 a-1 i show some exemplary embodiments of medical devicesaccording to the invention which include a stent (FIG. 1 a), a seed(FIG. 1 b), a cannula (FIG. 1 c), a bone anchor (FIG. 1 d), a sheet(FIG. 1 e), a plate (FIG. 1 f), a rod (FIG. 1 g), a plug (FIG. 1 h), anda constrictor (FIG. 1 i).

FIG. 2 is a cross-sectional schematic view of an embodiment of a medicaldevice according to the invention, illustrating the control ofresorption by swelling of embedded particles within the implantmaterial.

FIG. 3 is a cross-sectional schematic view of an embodiment of a medicaldevice according to the invention, illustrating the control ofresorption by hydrolysis of embedded particles within the implantmaterial.

FIG. 4 is a cross-sectional schematic view of an embodiment of a medicaldevice according to the invention, illustrating the control ofresorption by magnetic activation of embedded particles within theimplant material.

FIG. 5 is a cross-sectional schematic view of an embodiment of a medicaldevice according to the invention, illustrating the control ofresorption by providing a coating on the implant material.

FIG. 6 is a cross-sectional schematic view of an embodiment of a medicaldevice according to the invention, illustrating the control of deliveryof an embedded pharmaceutical agent.

DESCRIPTION

The resorption rate of a bioresorbable material used in medical implantsmay be controlled by effectively controlling the degree of porosity andthus the diffusion rate of a fluid in the implant material. The porosityof the implant material may be created or controlled by embedding in abulk material resorbable particles that resorb at a different and fasterrate than the bulk material. In general, the bioresorbable materialsforming the bulk component of the medical device are permeable tocertain body fluids including water and small ionizable moleculesdissolved therein. A body fluid is capable of penetrating the matrix ofthe bulk material through various mechanisms (e.g., diffusion,migration, or capillary action) to reach the embedded particles. Thefluid causes the resorbable particles to resorb once in contact with theparticles. The resorption of the particles leads to the formation ofvoids in the matrix of the bulk material. These voids contribute to anincrease in porosity of the bulk material, leading to a greater fluidflow in the matrix of the bulk material thereby speeding up itsbioresorption.

When the implant is broken into smaller fragments, the resorptionprocess becomes more effective and poses less health risks. Theexistence of large fragments of the implant could clog the flow of thebody fluid such as blood potentially causing serious complications.Therefore, by embedding resorbable particles that swell or move insidethe bulk implant material, the implant frame and large fragments of theimplant may be broken down into much smaller fragments. In addition,fragmentation increases the contact area with the body fluid therebyfacilitating resorption of the implant materials remaining in thefragments.

The porosity of the bulk material may also be increased by agitation ofthe particles within the matrix of the bulk material therebystructurally modifying or rupturing the matrix thereby creating voidsaround them. These voids are then available for the fluid flow asdescribed above. Accordingly, the present invention features resorbablemedical devices, and methods and compositions for achieving theircontrolled resorption.

Compositions and Medical Devices

In one aspect, the invention is directed to compositions useful in themanufacture of medical devices for use in a mammal. The compositionsinclude a bulk material that is bioresorbable and has resorbableparticles embedded therein. In another embodiment, the compositions mayinclude a bioresorbable bulk material that has magnetic particlesembedded therein.

The bioresorbable bulk material may be a reversibly ionicallycrosslinked polymeric material, which can include an ionicallycrosslinkable polymer and crosslinking ions. The ionically crosslinkablepolymeric material may be anionic or cationic and may include, but isnot limited to, at least one polymer or copolymer such as polyacrylicacids, polymethacrylic acid, polyethylene amine, polysaccharides,alginic acid, pectinic acids, carboxy methyl cellulose, hyaluronic acid,heparin, chitosan, carboxymethyl chitosan, carboxymethyl starch,carboxymethyl dextran, heparin sulfate, chondroitin sulfate, cationicstarch, and salts thereof. Illustrative examples of cationiccrosslinking ions include polycations such as calcium, magnesium,barium, strontium, boron, beryllium, aluminium, iron, copper, cobalt,lead, and silver ions. Illustrative examples of anionic crosslinkingions include polyanions such as phosphate, citrate, borate, succinate,maleate, adipate and oxalate ions, and, more broadly, anions derivedfrom polybasic organic or inorganic acids. In one embodiment, thecrosslinking cations are barium, and the crosslinking anions arephosphates. The bioresorbable bulk material may also be a reversibly,covalently crosslinked, polymeric material.

The bulk material may be a hydrogel having a water content of less than90% by weight and possessing sufficient mechanical strength to serve as,for example, a stent, a catheter, a cannula, a plug, a constrictor, asheet, a filler, a bone anchor, a plate, a rod, a seed, a tube, or aportion thereof. As used herein, the term “hydrogel” indicates amaterial that is water permeable, yet water insoluble in its crosslinkedform, but would release water-soluble components upon removal of thecrosslinks. A device may be in its hydrogel form or in a dehydratedform.

As used herein, a soluble material is a material that has a watersolubility such that upon exposure to a body fluid an amount of thematerial will dissolve or erode over time. “Body fluid” here refers tofluids in the body of a mammal including, but not limited to, blood,urine, saliva, lymph, plasma, gastric, biliary, or intestinal fluids,seminal fluids, and mucosal fluids or humors. A degradable material is amaterial that can decompose, degenerate, degrade, depolymerize, orotherwise reduce the molecular weight of the starting compound(s) suchthat the resulting compound(s) is soluble in water or, if insoluble, canbe suspended in a body fluid and transported away from the implantationsite without clogging the flow of the body fluid. A resorbable materialis a material that is soluble, degradable as defined above, or is anaggregate of soluble and/or degradable material(s) with insolublematerial(s) such that, with the resorption of the soluble and/ordegradable materials, the residual insoluble materials are ofsufficiently fine size such that they can be suspended in a body fluidand transported away from the implantation site without clogging theflow of the body fluid. Ultimately, the particles are eliminated fromthe body either by excretion in perspiration, urine or feces, ordissolved, degraded, corroded or otherwise metabolized into solublecomponents that are then excreted from the body. A bioresorbablematerial is a resorbable material that is biocompatible. A biocompatiblematerial is a material that is compatible with living tissue or a livingsystem, non-toxic or non-injurious and do not cause immunologicalreaction or rejection.

Generally, the particles embedded in the bioresorbable bulk materialfacilitate the resorption of the bioresorbable bulk material at acontrollable resorption rate upon contact with a body fluid. Thebioresorbable bulk material resorbs at a different and faster rate thanwhen it would if there were no particles embedded in the bulk material.The resorption rate of the bioresorbable material can be controlled byvarying the chemical and physical properties of the particles, theirsize, shape, amount, and distribution, etc. The particles may beresorbable or have magnetic properties. The resorbable particlesgenerally resorb at a different and faster rate than the bioresorbablebulk material. The resorbable particles may include a swelling agent, anhydrolysable agent, or a soluble agent or a combination thereof. Theseagents may be organic compounds, polymeric compounds, soluble ordegradable inorganic compounds, and/or organic or inorganic crystals orpowder aggregates. The particles may also include a polymeric material,e.g., polysaccharides, polyglycolic acid, polylactic acid, cellulosederivatives, hyaluronic acid, polylactams, hydrogels or other colloid.As an illustrative example, the resorbable particles may includeaggregates of metal oxides and a water-soluble component such as a gum,a sugar, or a salt. In these aggregates, the metal oxide may havemagnetic properties. The magnetic particles may also include a magneticmaterial coated with a protective coating to prevent degradation of themagnetic material by a body fluid and loss of magnetic properties.

In another aspect, the invention is directed to medical devices made ofthese compositions. Such medical devices include stents, catheters,cannulas, plugs, fillers, constrictors, sheets, bone anchors, plates,rods, seeds, tubes, or portions thereof. Exemplary medical devicesaccording to the invention are shown in FIGS. 1 a-i. Devices accordingto the invention may take many shapes or configurations other than thosedepicted in FIGS. 1 a-i, as these are only examples and are not intendedto encompass all the embodiments of the invention. Depending on theapplication, the entire device or one or more portions of the device maybe made of the bioresorbable compositions of the present invention.

FIG. 1 a depicts a tubular stent 100 that includes two coil-shaped endportions 102, a central portion 104, a lumen or passageway 106 withinthe tube from one end to the other. Stents may be used for maintainingthe patency of a body vessel such as, for example, urinary drainage fromthe kidney to the bladder in patients with uretertal obstruction orinjury, or to protect the integrity of the ureter in a variety ofsurgical manipulations. The device may be extruded or molded with thebioresorbable composition of this invention such that the entire deviceis made thereof or such that only one or more portions of the deviceinclude the compositions of the invention, such as one or both endportions 102, for example.

FIG. 1 b depicts a seed 110 shaped into an elongated pellet thatincludes an active substrate 112 (such as a medicine) within a shell orcoating 114 made of the resorbable composition according to theinvention. Alternatively, the medicine may be mixed throughout the seed,and the shape of the seed may be accommodated for the intended use intoother shapes, such as spherical, egg-shape, for example. Such seeds maybe used for delivering medicine to a specific organ such as in prostatehyperplasia and to provide control release of the medicine into theorgan upon resorption of the seed. See also, U.S. Pat. No. 4,697,575(incorporated herein by reference in its entirety). The entire devicemay be made of the bioresorbable material of the invention as the bulkmaterial with the medicine embedded therein that is introduced duringmanufacture. Alternatively, only the shell or coating 114 may be made ofthe bioresorbable material.

FIG. 1 c depicts a cannula 120 that includes a tube 122 and a lumen orpassageway 124. Cannulas are generally used to gain access to an organor vessel in a body percutaneously or through a natural body opening.Similarly to a cannula, a catheter is an elongated tube for insertionpercutaneously or through a natural body opening into a body cavity,duct, or vessel to allow the passage of a fluid or distend a passageway.Catheters are generally used for the drainage of urine from the bladderthrough the urethra, for insertion into a blood vessel for diagnosticpurposes, or to drain an abscessed area. A cannula or catheter may beextruded or molded with the bioresorbable composition of this inventionsuch that the entire device is made thereof or such that only one ormore portions of the device include the compositions of the invention,such as one or both end portions 122 or a middle section therebetweenfor example.

FIG. 1 d depicts a bone anchor 130 that includes anchoring legs 134, 136which include distal portions 138, 140, respectively, in the form oftapered cones separated by a slot 142. See U.S. Pat. No. 6,146,406(incorporated herein by reference in its entirety). Bone anchors arecommonly used to attach soft tissue to bone, e.g., during rotator cuffligament reconstruction. An anchor having an attached suture can beplaced into a bone hole. The suture can then be used to attach softtissue to the bone. It is beneficial to have the entire bone anchor orone or more portions, e.g., a portion of or the entire of one or bothlegs 134 and 136, made of the resorbable composition of the invention.After secure attachment of the soft tissue and the suture, the implantedbone anchor will then resorb over time without the need for surgicalremoval.

FIG. 1 e depicts a sheet 150 that includes a flexible and flat member152, a top surface 154 and bottom surface 156. For example, a sheet maybe used as anti-adhesion barrier to isolate tissues or organs such thatthey do not adhere to the organ or tissue. A sheet may be made with thebioresorbable composition of this invention such that the entire sheetis made thereof or such that only one or more portions of the sheetinclude the compositions of the invention, e.g., one or both surfaces154 and 156.

Similarly, as depicted in FIG. 1 f, a plate 160 includes a flat member162 that is typically rigid. For example, a plate may be used as anorgan support or as a space filler. A plate may be made with thebioresorbable composition of this invention such that the entire plateis made thereof or such that only one or more portions of the plateinclude the compositions of the invention, e.g., one or all corners 164.

As depicted in FIG. 1 g, a rod 170 includes an elongated member 172 andend portions 174. A rod may be made with the bioresorbable compositionof this invention such that the entire rod is made thereof or such thatonly one or more portions of the rod include the compositions of theinvention, e.g., one or both end portions 174 or a portion therebetween.For example, a plate may be used as an organ support or as a spacefiller.

FIG. 1 h depicts a plug 180 having a proximal end portion 182 and adistal end portion 184 that is usually used to stop fluid flow. A plugmay or may not be formed in situ. A plug may be made with thebioresorbable composition of this invention such that the entire plug ismade thereof or such that only one or more portions of the plug includethe compositions of the invention, e.g., one or both end portions 182and 184.

FIG. 1 i depicts a constrictor 190 that includes arms 192 and a bodyportion 194. A constrictor may be used to control the location of a bodypart or to prevent aneurysms. A constrictor may be made with thebioresorbable composition of this invention such that the entireconstrictor is made thereof or such that only one or more portions ofthe constrictor include the compositions of the invention, e.g., one orboth arm portions 192.

A medical device according to the invention can also be a filler, i.e.,one or more compositions that take the shape of a body cavity or bulk upthe tissue surrounding a body cavity. For example, a filler may be usedto fill up an aneurysm or assist in establishing control over thepassage of a body fluid such as in gastric or ureteral reflux, orurinary incontinence. In these applications, the bioresorbablecomposition of the invention is injected in the body cavity to be filledand bulked in the form of a gel or liquid and allowed to solidify byexposure to crosslinking mechanisms such as ionic or covalentcrosslinking mechanisms.

Referring to FIG. 2, which is a cross-sectional view of a tubularmedical device 210 such as a stent, the device 210 is fabricated from abulk bioresorbable material 220 with embedded resorbable particles 230.The resorbable particles 230, each of which has an agent that swellsupon contact with a body fluid, can be incorporated into thebioresorbable bulk material 220 during the manufacture of the device210, for example, by co-extrusion or molding. The inclusion ofresorbable particles 230 in the bioresorbable bulk material 220 and theresulting swelled particles 240 cause the medical implant to break upinto small fragments 250. The fragmentation process prevents largeimplant frame or fragments from clogging the flow of body fluids. Italso increases the contact area of the bioresorbable bulk material ofthe implant 210 with the body fluid. As a consequence, the diffusionrate of the fluid in the matrix increases, promoting resorption andmechanical degradation of the matrix structure of the medical implant.The swelling is especially effective when the ionic linkages arepartially removed as well as when outward diffusion of crosslinking ionshave weakened the mechanical strength of the remaining implant frame.

Referring to FIG. 3, which is a cross-section view, a medical device310, such as a stent, is fabricated from a bulk bioresorbable material320 having therein embedded resorbable particles 330. Resorbableparticles 330, each of which has an agent that hydrolyzes upon contactwith a body fluid, can also be incorporated into the bioresorbable bulkmaterial 320 during the manufacture of the medical device 310, forexample, by co-extrusion or molding. The agent hydrolyzes within thematrix upon contact with the body fluid. The embedded particles 330resorb by hydrolysis upon contact with the body fluid producingwater-soluble by-products. Hydrolysis of the particles produces voids340 and increases the porosity of the matrix of the bioresorbable bulkmaterial 320, resulting in an increased diffusion rate that promotesresorption and degradation of the bioresorbable bulk material 320. Thedevice as a result breaks into smaller fragments 350. The particles mayinclude a hydrolyzable polymer such as polysaccharides, polyglycolicacid, polylactic acid, polycaprolactone, or copolymers of any two orthree of glycolic acid, lactic acid, and caprolactone monomers.

Referring to FIG. 4, which is a cross-sectional view, a medical device410, such as a stent, is fabricated from a bulk resorbable material 420having therein embedded particles 430. Each of the particles 430 mayinclude one or more materials with magnetic, paramagnetic, and/orsuperparamagnetic (generally referred to hereinafter as simply“magnetic”) properties. The particles 430 having magnetic properties maybe embedded into the bioresorbable bulk material 420 during themanufacture of a medical device 410, for example, by co-extrusion ormolding. The embedded particles 430 can be transiently or continuouslystimulated by the use of a magnetic field, such as an oscillatingmagnetic field 440. The embedded particles 430 respond to the magneticfield by moving and/or vibrating within the matrix of the bioresorbablebulk material thereby causing fragmentation of the implant frame,producing small pieces 450 with increased contact area with the bodyfluid. As a consequence, diffusion and resorption rates are increasedwhile risk of clogging the flow of the body fluid and relatedcomplications decreased. The particles can be of any shape as long asthe particles possess the desired magnetic property. As illustrativeexamples, the shape of the particles may be in an elongated form such asa rod or oblong, but spherical or other shapes may also be used. Certainshapes such as those with sharp edges may break the frame of the bulkimplant material more easily than particles with more smooth edges.Suitable materials having the desired magnetic properties are well knownin the art. Illustrative examples of magnetic materials that may beemployed in this invention include metals, alloys, and metal oxides(such as iron, nickel, cobalt, gadolinium, other transition metalspossessing ferromagnetic properties, and alloys or oxides thereof).

The resorption rate may be controlled by varying the size and amount(e.g., the volume percentage) of the aforementioned particles. The sizeof the particles or the size of the aggregates of particles is notcritical so long as the particles are capable of causing fragmentationof the implant frame and afterwards being eliminated from the body byexcretion, without triggering inflammation or blockage of fluid flow, orare capable of resorption by dissolution, degradation, disintegration ormetabolic pathway. For illustration purposes, the size of the particlesmay be from about 5 nm to about 1 mm depending on the type of theimplant. In some applications, the preferred size can vary from 5 mm to1 .mu.m. In other applications, the preferred size can vary from 1 .mu.mto 100 .mu.m, 100 .mu.m to 500 .mu.m, or 500 .mu.m to 1 mm. There is norequirement that all the particles be of the same size.

The distribution of the particles in the bioresorbable bulk materialneed not be uniform, but uniformity may be preferred in certaincircumstances. For example, concentration of embedded particles may behigher in the pigtail region of a ureteral stent to favor fasterdissolution and quicker removal of the stent from the ureter. The volumepercentage of the particles in the bioresorbable bulk material can beequal to or less than about 50% depending on factors including theparticularities of the implant. In some embodiments, the volumepercentage is less than 1% or greater, up to 50%.

The particles may be made of the same types of polymeric material as thebulk material but with a substantially different characteristics suchthat their resorption occur at a greater rate than the resorption of thebulk material such as lower molecular weight, lower crosslinking ratio(e.g., the number of crosslinks per crosslinkable sites or the number ofcrosslinks per unit volume or weight of the material), or differentcrosslinking ions (e.g. ions of a weaker electronic affinity).Characteristics of the polymeric material can be modulated by modifyingfactors such as these to suit the specific application at hand.

Controlling Resorption

In another aspect, the invention generally features methods forcontrolling resorption of a bioresorbable material for use in a medicaldevice in a mammal In one embodiment, a method for controllingresorption of a bioresorbable material in a medical device includes thesteps of providing a bioresorbable bulk material, embedding resorbableparticles in the bioresorbable bulk material, and contacting a bodyfluid with the bioresorbable bulk material having the embedded particlesthereby causing the bioresorbable bulk material to resorb at acontrollable resorption rate. The embedded particles have a differentand faster resorption rate from that of the bulk material. Theresorption rate of the bioresorbable bulk material is typicallycontrolled to be faster with particles embedded in it than theresorption rate of the bioresorbable bulk material without the embeddedparticles.

Referring to FIG. 2 again and in one embodiment, the bioresorption iscontrolled by the swelling of the embedded particles 230 upon contactwith a body fluid. Swelling may arise from, but is not limited to,chemical reactions or physical interactions upon the contact of theparticles with a body fluid, such as the capture of some body fluid bythe particle as in hydration, or release of gases. Continued swelling ofthe particles 240 weakens the matrix structure of the bioresorbable bulkmaterial 220 and causes the medical implant frame to break up into smallfragments 250, thereby preventing the large implant frame or fragmentsfrom clogging the flow of the body fluid. In addition, fragmentationinto small pieces also results in an increased contact area of thebioresorbable bulk material 220 with the body fluid. The consequence isan increased fluid diffusion rate that promotes resorption and leads tothe eventual mechanical degradation of the bioresorbable bulk material.

In one embodiment, particles having an agent that swells upon contactwith the body fluid are incorporated into the bioresorbable bulkmaterial during manufacture of a medical device. The agent and theparticles swell within the matrix of the bioresorbable bulk materialupon contact with the body fluid. In the case of ionically crosslinkedpolymeric materials, the swelling is especially effective in breaking upthe implant frame after the ionic linkages of the crosslinked polymericmaterial have been partially removed by diffusion of crosslinking ionsout of the matrix or by other means. The resorption rate of the implantcan be modulated to fit a particular need. Typically, the presence ofthe particles favors a more homogeneous resorption of the implantmaterial. Variance in the size of the fragments and in turn theresorption rate of the implant material may be achieved by varying thesize, amount, shape, distribution, and/or nature of the particles withinthe implant. For example, a medical device may be manufactured withhigher concentrations of highly swellable particles in the inner core ofthe device so as to have a slow onset of the resorption, followed by arapid resorption of the inner core. Higher concentration may be used onan outer shell of the device to obtain an opposite result. For example,in the case of a ureteral stent, faster resorption of the kidney tail ofthe stent than the body of the stent may be desirable to favor theelimination or transportation of the stent out of the ureter into thebladder in a minimal amount of fragments. The partly resorbed stentwould then continue to resorb at a slower rate into the bladder.

Referring to FIG. 3 again and in another embodiment, the bioresorptionis controlled by the hydrolysis of the particles upon contact with abody fluid producing soluble by-products. Hydrolysis of the particles330 into soluble by-products results in voids 340 in the matrix of thebioresorbable bulk material 320 and an increased porosity. As aconsequence, the diffusion rate of the fluid into the implant 310increases thereby promoting resorption and the eventual mechanicaldegradation of the material structure of the implant. The device as aresult breaks into smaller fragments 350. In one embodiment, particleshaving an agent that hydrolyzes upon contact with the body fluid areincorporated into the bioresorbable bulk material during the manufactureof a medical implant device. The agent hydrolyzes within the matrix ofthe bioresorbable bulk material upon contact with the body fluid.Similar to the swelling agent, the resorption rate can be controlled byvarying the size, shape, amount, and/or nature of the particles embeddedin the bioresorbable bulk material. The resorption rate is alsodependent on the hydrolizable agent and its amount used in theparticles.

Referring to FIG. 4 again and in another embodiment, the bioresorptionis controlled by activation and/or vibration of the embedded particlesresponding to a magnetic field. The methods for controlling resorptionof a bioresorbable material include providing a bulk material 420 thatis bioresorbable and is embedded with particles 430 having magnetic,paramagnetic, and/or superparamagnetic properties, creating a magneticfield surrounding the particles, and inducing activation or vibration ofthe particles by modulating the magnetic field 440 thereby causingresorption of the bulk material at a controllable rate. The implantbreaks into smaller fragments 450. These particles may include amagnetic material, a paramagnetic material, and/or a superparamagneticmaterial.

In one detailed embodiment, inducing activation and/or vibration of theparticles is by time-varying the magnetic field surrounding theparticles. The magnetic field establishes forces that compel themagnetic, paramagnetic, or superparamagnetic particles to move withinthe matrix of the material lodging the particles. The moving and/orvibrating of the embedded particles within the matrix of thebioresorbable bulk material causes fragmentation of the implant frame,producing small pieces with increased contact area with a body fluid. Asa consequence, diffusion and resorption rates are increased while riskof clogging the fluid flow and related complications decreased. Themagnetic field surrounding the particles may be supplied by a magneticfield generator within the body of the subject being treated. Themagnetic field can also be supplied by a magnetic field generatoroutside of the subject's body. The field strength of the magnetic fieldthat may be employed depends on the size and nature of the particles andthe desired rate of resorption. In one embodiment, the magnetic field atthe site is oscillating in strength as a function of time and/orcoordination. The resorption rate can also be controlled by varying thesize, shape, and/or amount of the particles embedded in thebioresorbable bulk material. Furthermore, the resorption rate isdependent on the nature and amount of the magnetic material used in theparticles and the orientation of the particles relative to the magneticfield.

Similarly, particles that respond to microwave, ultrasound, or radiofrequencies may be embedded in the implant bulk material. Movement orvibration of these particles responding to microwave, ultrasound, orradio frequencies causes fragmentation of the implant frame.

In another embodiment, as illustrated in FIG. 5, resorption of abioresorbable material is controlled by a coating on a medical device.The methods for controlling resorption of a bioresorbable materialinclude providing a bulk material 520 that is bioresorbable and shapedas a medical device, here a stent 510, and coating the medical devicewith a coating material 530. The coating material 530 includes adissolvable polymeric material and allows diffusion of a body fluidthrough the coating material at a pre-selected rate. Coating of themedical device may be by any conventional coating methods includingsolvent and hot-melt processes. The medical device can be completely oronly partially coated. The diffusion rate can be controlled by varyingthe size, thickness, and/or the nature of the coating material on thedevice. For example, a coating that is more hydrophobic tends to slowdown the diffusion rate into the implant.

In yet another aspect, the invention features a coating material for usein a medical device for regulating resorption of the medical device. Thecoating serves as a controlled barrier to diffusion. The coatingmaterial includes a bioresorbable ionically or covalently crosslinkedpolymeric material that allows diffusion into the medical device by abody fluid at a pre-selected rate. The device can be completely or onlypartially coated. Illustrative examples of such coating material includea hydrogel, such as hyaluronic acid and polyslip, and thermoplasticmaterial, such as polyurethane and polyethylene. The coating materialmay be applied to a device by melt, solvent, spray or other processesknown to the artisan. The coating material can also include alubricity-controlling agent.

Referring to FIG. 6, a system can be constructed for a controlleddelivery of a pre-selected pharmaceutical agent to a location within thebody of a mammal This system includes a carrier device 610 with acoating that has a bioresorbable ionically or covalently crosslinkedpolymeric material. The pharmaceutical agent to be delivered can beincorporated into the coating material 620 as macro-particles embeddedtherein. The pharmaceutical agent can also be incorporated into thecoating material in bulk at the molecular level. The pharmaceuticalagent 630 diffuses out of the coating material 620 upon contacting abody fluid by the coating material 620. The inner core 640 may beconstructed to provide necessary mechanical support for the coatinglayer. The inner core 640 may or may not be needed depending on theapplication. The carrier can be any device that is capable of carryingthe pre-selected pharmaceutical agent such as antimicrobial orantibiotic agents. The agent loading can generally be from about 0.01%to about 40% depending on the agent and the need of the treatment.

Compositions of the present invention may be produced by anyconventional ways of forming a mixture with two or more components. Thecompositions may be prepared by mixing precursor components followed bya chemical processing of either the particles or the bulk material. Forexample, a conventional mechanical mixer may be sufficient to produce acomposition having particles of desired properties and a bioresorbablematerial. A solvent may be used so that a solution of the bulkbioresorbable material is mixed with the particles followed by removalof the solvent. Such methods include first mixing precursor(s) of thebioresorbable bulk material with the particles followed by a reaction ofthe precursor(s) to produce the bioresorbable bulk material. Also, onecan first mix precursor(s) of the particles with the bioresorbable bulkmaterial followed by a reaction of the precursor(s) to produce thedesired particles. Chemical modifications that may be used in preparingthe compositions of the invention include, but are not limited to,polymerization, crosslinking reactions either ionic or covalent so as togel, cure, or set a precursor polymer.

The devices (or components of devices) of the present invention may bemade via various manufacturing processes including injection molding,extrusion, rotational molding, compression, roll wrapping, etc. Forexample, one way to produce a stent is to first mix particles of thedesired properties with an extrudable and bioresorbable material andthen extrude the mixture to form a stent using conventional extrusiontechniques. Another method is to wrap a sheet or film of the mixturearound a cone-shaped mandrel. Yet another method is to employ apultrusion process where the mixture of the bioresorbable material andparticles are pulled from a pultrusion die having the desiredcross-sectional profile.

The devices of the present invention may be used for any treatmentinvolving a medical implant that needs a controlled resorption rate. Forexample, a ureteral stent made with the compositions of the presentinvention may be placed in a patient. The stent will then resorb at arate dependent on the composition of the material. The stent can be setto resorb quickly or slowly by pre-selecting its composition asdescribed earlier. Devices can also be constructed to effect drugdelivery as described above.

EXAMPLE 1

A syringe pump is connected to three syringes. Syringe One contains analginate solution. Syringe Two contains a calcium carbonate solution.Syringe Three contains the same alginate solution as in Syringe One plusresorbable fine particles of an alginate at a different molecular weightthan that in Syringe One. The contents of the three syringes areinjected into a tube connected to the three syringes and then pushedinto a static mixer made of silicone tubing. After mixing, the contentof the static mixer then travels to a tubular shaped cavity and a rod sopositioned that a tubular shaped device is molded and gels.Alternatively, a port having the desired features can be used to form adesired medical device. Normally, extrusion is first done into a low pHbuffer solution wherein calcium ions partially diffuse out. A secondcrosslinking is then carried out producing the final device.

EXAMPLE 2

Example 1 is repeated except resorbable fine particles having polylacticacid are used.

EXAMPLE 3

A segment of the tubing produced in Example 1 is soaked in a simulatedbody fluid such as urine for 48 hours. Samples from the soaked tubingare placed under a microscope and compared with samples from an unsoakedtubing. It is expected that the soaked samples will have broken downinto fragments or display cracking in the frame of the implant.

EXAMPLE 4

A segment of the tubing produced in Example 2 is soaked in a simulatedbody fluid such as urine for 48 hours. Samples from the soaked tubingare placed under microscope and compared with samples from the unsoakedtubing. It is expected that the soaked samples will exhibitsignificantly hydrolyzed particles and voids so created.

Variations, modifications, and other implementations of what isdescribed herein will occur to those of ordinary skill in the artwithout departing from the spirit and the scope of the invention.Accordingly, the invention is not to be limited by the precedingillustrative description.

1-20. (canceled)
 21. A coating material for use in a medical device forregulating resorption of said medical device, said coating materialcomprising (a) a bioresorbable ionically or covalently crosslinkedpolymeric material that allows diffusion into said medical device by abody fluid at a pre-selected rate; and (b) particles embedded in saidbioresorbable polymeric material, said particles causing saidbioresorbable polymeric material to resorb upon contact with a bodyfluid at a controllable resorption rate.
 22. The coating material ofclaim 1, wherein the resorption of said bioresorbable polymeric materialis further controlled by varying the size or the amount of said embeddedparticles.
 23. The coating material of claim 1, wherein saidcontrollable resorption rate is different from a resorption rate of saidbioresorbable polymeric material without said embedded particles. 24.The coating of claim composition of claim 1, wherein said bioresorbablepolymeric material comprises an ionically cross-linkable polymericmaterial comprises at least one polymer or copolymer that can be madefrom at least one member of the group consisting of polyacrylic acids,polymethacrylic acid, polyethylene amine, polysaccharides, alginic acid,pectinic acids, carboxy methyl cellulose, hyaluronic acid, heparin,chitosan, carboxymethyl chitosan, carboxymethyl starch, carboxymethyldextran, heparin sulfate, chondroitin sulfate, cationic starch, andsalts thereof.
 25. The coating of claim 1, further comprising apharmaceutical agent.
 26. The device of claim 25, wherein thepharmaceutical agent is incorporated within said bioresorbable bulkmaterial.
 27. A medical device for use in a mammal comprising: (a) abioresorbable bulk material; (b) particles embedded in saidbioresorbable bulk material, said particles causing said bioresorbablebulk material to resorb upon contact with a body fluid at a controllableresorption rate, wherein said bioresorbable bulk material comprises aninjectable material in the form of a gel or liquid.
 28. The device ofclaim 27, wherein said bioresorbable bulk material comprises a polymericmaterial that solidifies upon exposure to crosslinking mechanismscomprising ionic or covalent crosslinking mechanisms.
 29. The device ofclaim 27, wherein said bioresorbable bulk material comprises anionically cross-linkable polymeric material.
 30. The device of claim 27,wherein said bioresorbable bulk material comprises a covalentlycrosslinkable polymeric material.
 31. The device of claim 27, whereinthe resorption of said bioresorbable material is further controlled byvarying the size or the amount of said embedded particles.
 32. Thedevice of claim 27, wherein said controllable resorption rate isdifferent from a resorption rate of said bioresorbable bulk materialwithout said embedded particles.
 33. The device of claim 27, whereinsaid bioresorbable bulk material comprises a filler that conforms to ashape of a body cavity or bulks up tissue surrounding a body cavity. 34.The device of claim 27, wherein the bioresorbable bulk material is afiller for filling an aneurysm.
 35. The device of claim 27, wherein saidparticles embedded in said bioresorbable bulk material have a resorptionrate that is different from a resorption rate of said bioresorbable bulkmaterial.
 36. The device of claim 27, wherein said particles embedded insaid bioresorbable bulk material swell upon contact with a body fluid.37. The device of claim 27, wherein said particles embedded in saidbioresorbable bulk material comprise an agent which hydrolyzes intosoluble by-products upon contact with a body fluid.
 38. The device ofclaim 27, wherein the device comprises a constrictor to control thepassage of fluid in a body part.
 39. The device of claim 38, wherein thebody part comprises a gastric tract or urinary tract.
 40. The device ofclaim 27, wherein said bioresorbable bulk material comprises anionically cross-linkable polymeric material comprising at least onepolymer or copolymer that can be made from at least one member of thegroup consisting of polyacrylic acids, polymethacrylic acid,polyethylene amine, polysaccharides, alginic acid, pectinic acids,carboxy methyl cellulose, hyaluronic acid, heparin, chitosan,carboxymethyl chitosan, carboxymethyl starch, carboxymethyl dextran,heparin sulfate, chondroitin sulfate, cationic starch, and saltsthereof.
 41. The device of claim 27, further comprising a pharmaceuticalagent.
 42. The device of claim 41, wherein the pharmaceutical agent isincorporated within said bioresorbable bulk material.